Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways
Vincenzo Quagliariello(Cancer Institute (WIA)), Nicola Maurea(Cancer Institute (WIA)), Giuseppe Palma(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giuseppina Gallucci, Margherita Passariello(Federico II University Hospital), Simona Buccolo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Ciro Cipullo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Antônio Barbieri, Andrea Paccone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Claudia De Lorenzo(Istituto Nazionale di Fisica Nucleare, Sezione di Napoli), Alessandro Inno(Ospedale Sacro Cuore Don Calabria), Maria Laura Canale(Ospedale Versilia), Annabella Di Mauro(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Irma Bisceglia(Azienda Ospedaliera San Camillo-Forlanini), Antonio Luciano(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cited by 48
Related Papers
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy
|Critical Reviews in Oncology/Hematology|2019|164
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
|Journal of Cardiac Failure|2011|116
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience
|Cancer Biology & Therapy|2010|108
Resveratrol in Cancer Patients: From Bench to Bedside
|International Journal of Molecular Sciences|2020|105